Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

(Reuters) -Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top ...

The electronic health records market is experiencing robust growth, primarily driven by the increasing incidence of chronic diseases that require ong ...

The drug candidate, trevogrumab, in combination with Novo Nordisk's popular obesity drug Wegovy, chemically known as semaglutide, helped patients preserve muscle and increase fat loss in patients, ...

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO ... THE U.S. MARKET Trump, who campaigned on a promise to boost domestic manufacturing, has been piling pressure on drugmakers since ...

Novo Nordisk has ... as it pushes to boost its pipeline of potential blockbuster medicines. The UK-listed pharmaceuticals group said on Wednesday it would give US company Boston ...

Shares of Novo Nordisk closed around 1% lower on Thursday, while Eli Lilly's stock closed more than 11% lower. It comes as Novo Nordisk works to boost access ... across the US healthcare system ...

Novo Nordisk, a leading global healthcare company, has announced the signing of a MoU with Lifera, a biopharmaceutical company owned by the Saudi sovereign wealth fund PIF (Public Investment Fund), to ...

The MOU marks a significant step in strengthening the Kingdom’s healthcare sector and pharmaceutical manufacturing ... at Novo Nordisk. “By localizing production, we are enhancing access to our ...